ReviewInternational ophthalmology2021
Diabetic retinal neurodegeneration as a form of diabetic retinopathy.
Review in International ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 56 citations in OpenAlex.
- Epac1 deletion attenuates Müller glial pathological activation and mitigates retinal neurodegeneration in ischemia-induced retinopathy.Journal of advanced research · 2026Article
- Targeting endoplasmic reticulum stress in diabetic retinopathy: mechanistic insights and emerging therapies.Biological research · 2026Review
- Neurovascular unit uncoupling in diabetic retinopathy: molecular mechanisms and stage-adapted therapeutic strategies.Frontiers in endocrinology · 2026Review
- Elucidating the mechanism by which Aloe-emodin from Cassiae semen treats diabetic retinopathy via network pharmacology and experimental verification.Scientific reports · 2025Article
- The Role of Non-coding RNAs in Diabetic Retinopathy: Mechanistic Insights and Therapeutic Potential.Molecular neurobiology · 2025Review
- Elucidating programmed cell death in diabetic retinal microangionopathy and neurodegeneration: unraveling molecular mechanisms and therapeutic actions of natural products.Inflammopharmacology · 2025Review
- Enhancing Retinal Resilience: The Neuroprotective Promise of BDNF in Diabetic Retinopathy.Life (Basel, Switzerland) · 2025Review
- Collagen mimetic peptides as novel therapeutics for vascular disease in the central nervous system.Frontiers in neuroscience · 2025Article
- Therapeutic Effects of Metformin on Central Nervous System Diseases: A Focus on Protection of Neurovascular Unit.Pharmaceutical research · 2024Review
- Retinal age gap as a predictive biomarker for future risk of clinically significant diabetic retinopathy.Acta diabetologica · 2024Article
- Visual processing speed and its association with future dementia development in a population-based prospective cohort: EPIC-Norfolk.Scientific reports · 2024Article
- Modelling neurodegeneration and inflammation in early diabetic retinopathy using 3D human retinal organoids.In vitro models · 2024Article
- Multi-omics in exploring the pathophysiology of diabetic retinopathy.Frontiers in cell and developmental biology · 2024Review
- DJ-1 regulates mitochondrial function and promotes retinal ganglion cell survival under high glucose-induced oxidative stress.Frontiers in pharmacology · 2024Article
- Effects of mesenchymal stromal cells and human recombinant Nerve Growth Factor delivered by bioengineered human corneal lenticule on an innovative model of diabetic retinopathy.Frontiers in endocrinology · 2024Article
- Insulin resistance in the retina: possible implications for certain ocular diseases.Frontiers in endocrinology · 2024Review
- Inhibition of Ferroptosis Ameliorates Photoreceptor Degeneration in Experimental Diabetic Mice.International journal of molecular sciences · 2023Article
- Is metformin neuroprotective against diabetes mellitus-induced neurodegeneration? An updated graphical review of molecular basis.Pharmacological reports : PR · 2023Review
- Intraocular Microbiome in Diabetes and Diabetic Retinopathy: A Pilot Study.Ophthalmology and therapy · 2023Article
- Optic Nerve Regeneration in Diabetic Retinopathy: Potentials and Challenges Ahead.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo review the evidence supporting diabetic retinal neurodegeneration (DRN) as a form of diabetic retinopathy.
methodReview of literature.
resultsDRN is recognized to be a part of retinopathy in patients with diabetes mellitus (DM), in addition to the well-established diabetic retinal vasculopathy (DRV). DRN has been noted in the early stages of DM, before the onset of clinically evident diabetic retinopathy. The occurrence of DRN has been confirmed in animal models of DM, histopathological examination of donor's eyes from diabetic individuals and assessment of neural structure and function in humans. DRN involves alterations in retinal ganglion cells, photoreceptors, amacrine cells and bipolar cells, and is thought to be driven by glutamate, oxidative stress and dysregulation of neuroprotective factors in the retina. Potential therapeutic options for DRN are under evaluation.
conclusionsLiterature is divided on the temporal relation between DRN and DRV, with evidence of both precedence and simultaneous occurrence. The relationship between DRN and multi-system neuropathy in DM is yet to be evaluated critically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.